Related content

An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease

By  

VOX SANGUINIS, Vol. 109, Iss. 3, 2015-10 ,pp. : 248-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Test Dose Pharmacokinetics in Pediatric Patients Receiving Once‐Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 3, 2018-03 ,pp. : 332-339

John Wiley & Sons Inc

Access to resources Recommend Favorite

New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 4, 2015-04 ,pp. : 680-686

John Wiley & Sons Inc

Access to resources Recommend Favorite

The importance of vaccination and immunoglobulin treatment for patients with primary immunodeficiency diseases (PIDs) ‐ World PI Week April 22–29, 2015

By  

EUROPEAN JOURNAL OF IMMUNOLOGY, Vol. 45, Iss. 5, 2015-05 ,pp. : 1285-1286

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 3, 2015-03 ,pp. : 477-482

John Wiley & Sons Inc

Access to resources Recommend Favorite